Commentary

You have free access to this content

Exploiting new targets for old bones

  1. Clifford J Rosen MD*

Article first published online: 26 MAR 2010

DOI: 10.1002/jbmr.91

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 5, pages 934–936, May 2010

Additional Information

How to Cite

Rosen, C. J. (2010), Exploiting new targets for old bones. J Bone Miner Res, 25: 934–936. doi: 10.1002/jbmr.91

Author Information

  1. Maine Medical Center Research Institute, Scarborough, ME 04074, USA

*Director, Clinical and Translational Medicine, Maine Medical Center Research Institute, Scarborough, Maine, USA.

Publication History

  1. Issue published online: 30 APR 2010
  2. Article first published online: 26 MAR 2010
  3. Accepted manuscript online: 26 MAR 2010 12:00AM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (49K)

References

  • 1
    Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Min Res. 2010; 25: 937–949.
  • 2
    Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of scelerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Min Res. 2010; 25: 948–959.
    Direct Link:
  • 3
    Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progesterone on the risk of fractures and bone density. JAMA. 2003; 290: 1729–1738.
  • 4
    Eghbali-Faourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANKL in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2002; 111: 1221–1230.
  • 5
    Lenart B, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358: 1304–1306.
  • 6
    Li X, Zhang Y, Kang H, et al. Sclerostin binds to Lrp5 and Lrp6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883–19887.
  • 7
    Ott SM. Revie of sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab. 2005; 90: 6741–6743.
  • 8
    Brunkow ME, Garner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from the loss of the SOST gene product, a novel cystine knot containing protein. Am J Hum Genet. 2001; 68: 577–589.
  • 9
    Leuptin O, Kramer I, Colette NM, et al. Control of the SOST bone enhancer by PTH by using MEF2 transcription factors. J Bone Miner Res. 2007; 22: 1957–1967 .
    Direct Link:
  • 10
    Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Min Res. 2006; 21: 366–373.
    Direct Link:
  • 11
    Yadav VK, Balaji S, Suresh P, et al. Pharmacologic inhibition of gut derived derotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010 (in press).
View Full Article (HTML) Get PDF (49K)